Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions

Abstract

The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-γ is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-γ is increased by about 20 to 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-γ is in a ratio such that after 60 h of activation with IFN-γ, the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-γ activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.

What is claimed:  
     
         1 . A method of treating cancer, comprising administering to a patient in need of said treatment, an effective amount of macrophages produced by culturing monocytes in vitro, said macrophages having at least one of the following properties: 
 their cytotoxic activity without IFN-γ is increased by about 20 to 30% with respect to standard macrophages;    their cytotoxic activity is increased with IFN-γ by about 20 to 40% with respect to standard macrophages;    deactivation of the cytotoxic activity following activation of IFN-γ is such that sixty hours after activation with IFN-γ, the residual cytotoxic activity is at least 30% of the maximum cytotoxic activity presented by the macrophages due to IFN-γ activation, with said cytotoxic activity being measured as a percentage of the inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.    
     
     
         2 . The method as claimed in  claim 1 , wherein said effective amount is about 10 8  to about 5×10 9  macrophages.  
     
     
         3 . The method as claimed in  claim 1 , wherein said effective amount is about 2×10 9  to about 5×10 9  macrophages.  
     
     
         4 . The method as claimed in  claim 1 , wherein the said method further comprises administering lymphocytes to said patient.  
     
     
         5 . The method according to  claim 1 , wherein said macrophages contain exogenous nucleic acids and/or drugs.